ADMA Biologics

company

About

ADMA Biologics develops plasma-based biologics for the treatment and prevention of certain infectious diseases.

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$5M
Industries
Biotechnology,Health Care,Manufacturing,Medical
Founded date
Jan 1, 2004
Number Of Employee
51 - 100
Operating Status
Active
Stock Symbol
nasdaq:ADMA
Legal Name
ADMA PLASMA BIOLOGICS INC.

ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons.

ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
16
$607.35M
ADMA Biologics has raised a total of $607.35M in funding over 2 rounds. Their latest funding was raised on Dec 7, 2022 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 7, 2022 Post-IPO Equity $60M Detail
Mar 24, 2022 Post-IPO Debt $150M 1 Hayfin Capital Management Detail
Feb 6, 2020 Post-IPO Equity $82.30M Detail
May 22, 2019 Post-IPO Equity $51.75M Detail
Feb 12, 2019 Post-IPO Debt $72.50M 1 Perceptive Advisors Detail

Investors

Number of Lead Investors
Number of Investors
7
8
ADMA Biologics is funded by 8 investors. Hayfin Capital Management and Perceptive Advisors are the most recent investors.
Investor Name Lead Investor Funding Round
Hayfin Capital Management Yes Post-IPO Debt
Perceptive Advisors Yes Post-IPO Debt
Marathon Asset Management Yes Post-IPO Debt
Oxford Finance LLC Yes Post-IPO Debt
Burrill & Company Yes Series Unknown
Hercules Capital Post-IPO Debt
Aisling Capital Series Unknown
Biomark Capital Series Unknown

Employee Profiles

Number of Employee Profiles
9
ADMA Biologics has 9 current employee profiles, including Executive Bryant E. Fong
Executive
Board member
Employee
Board member

Acquisition

ADMA Biologics has acquired 1 organizations. Their most recent acquisition was Biotest - Therapy business on Jun 6, 2017. They acquired Biotest - Therapy business for 0.

Date Company Name
Industry Acquisition Type Price
Biotechnology acquisition Detail